These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 20145517)

  • 21. Antibody-mediated rejection in kidney transplantation: an update.
    Lucas JG; Co JP; Nwaogwugwu UT; Dosani I; Sureshkumar KK
    Expert Opin Pharmacother; 2011 Mar; 12(4):579-92. PubMed ID: 21294653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
    Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA
    Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
    Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
    Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
    Ejaz NS; Alloway RR; Halleck F; Dürr M; Budde K; Woodle ES
    Antioxid Redox Signal; 2014 Dec; 21(17):2401-18. PubMed ID: 24635140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
    Manitpisitkul W; Wilson N; Cooper M; Gurk-Turner C; Hurley H; Rasetto F; KuKuruga D; Barth RN; Philosophe B
    Clin Transpl; 2009; ():461-3. PubMed ID: 20524315
    [No Abstract]   [Full Text] [Related]  

  • 26. Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
    Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
    [No Abstract]   [Full Text] [Related]  

  • 27. Bortezomib for acute humoral rejection in two repeat transplant recipients.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-mediated rejection: treatment alternatives and outcomes.
    Singh N; Pirsch J; Samaniego M
    Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and investigational use of proteasome inhibitors for transplant rejection.
    Sadaka B; Alloway RR; Woodle ES
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durability of antibody removal following proteasome inhibitor-based therapy.
    Everly MJ; Terasaki PI; Trivedi HL
    Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
    Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
    Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
    Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
    Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
    Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
    Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
    Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
    Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
    Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
    Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
    Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.